Health News Releases

April 10, 2015 19:00

Replicor to Present at the 2015 Lancet Viral Hepatitis Conference

Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will present updated cli

April 10, 2015 17:00

IBA and Toshiba Sign Strategic Partnership in Particle Therapy

IBA (Ion Beam Applications S.A.) and Toshiba Corporation (TOKYO:6502) today announce the signing of a global collaboration to expand access to advanced particle therapy worldwide. Toshiba Medical Syst

April 10, 2015 13:15

Quintiles wins Best CRO Award at World Vaccine Congress 2015

For the third time in the last four years, Quintiles has been named Best Clinical Research Organization (CRO) at the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress i

April 09, 2015 11:45

PPD and SNBL Complete Joint Venture to Provide Japanese Clinical Development Services and Additional Collaborations

Pharmaceutical Product Development, LLC (PPD, www.ppdi.com) and Shin Nippon Biomedical Laboratories Ltd. (SNBL, http://snbl.com) (TSE:2395) today announced the closing of an agreement to form a joint

April 03, 2015 13:50

TPG Completes Acquisition of Aptalis Pharmaceutical Technologies, Company Renamed Adare Pharmaceuticals

Aptalis Pharmaceutical Technologies announced today that its divestiture from Actavis plc to TPG, a global private investment firm, has been completed. The company also announced that its new name is

April 01, 2015 11:25

Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services

Quintiles (www.quintiles.com) and Quest Diagnostics (http://goo.gl/NbIXp) today announced a definitive agreement to form a global clinical trials laboratory services business. By combining the clinica

March 31, 2015 06:00

World's Largest and Fully-Integrated Healthcare Exhibition “tHIS 2015” to Break Attendance Records This May

The Health Industry Summit (tHIS) 2015 organized by Reed Sinopharm will be held on May 15-18, 2015, at the National Convention & Exhibitions Center in Shanghai, China. Latest figures indicate that the

March 30, 2015 16:15

Type 2 Diabetes: CHMP Recommends Empagliflozin/Metformin Hydrochloride for Approval in the European Union

For media outside the US, the UK and Canada only Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) today announced they have received a positive opinion from the Committee for Medicinal P

March 27, 2015 15:45

Galderma Announces Positive Outcome of European Decentralised Procedure for Approval of SOOLANTRA® (ivermectin) Cream 10mg/g for Rosacea Patients

Galderma, a global specialty pharmaceutical company focused on dermatology, announced today a positive outcome of the European Decentralised Procedure (DCP) for SOOLANTRA® (ivermectin) Cream 10mg/g fo

March 25, 2015 14:00

Quintiles’ Anand Tharmaratnam Honored as ‘Asian Male Executive of the Year’ in BioPharma Asia Industry Awards 2015

Quintiles Head of Asia Markets Anand Tharmaratnam (http://goo.gl/KFkhvE), M.D., last night was honored as “Best Life Science Asian Male Executive of the Year” at the BioPharma Asia Industry Awards. Dr

March 24, 2015 13:20

THERAVECTYS Granted Authorization by the French National Agency for Medicines to Produce Lentiviral Vectors for Clinical Use and CAR-T Cell Therapies under GMP Standards

THERAVECTYS (www.theravectys.com), a clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapies, proudly announces that its manufacturing plant

March 24, 2015 09:30

Biogen Idec Becomes Biogen

Effective today, Biogen Idec is known simply as Biogen (https://www.biogen.com) (NASDAQ: BIIB). The company has introduced a new corporate identity and logo that reflect both its evolution and focus o

March 23, 2015 13:20

Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study

For non-UK/non-Canadian media only For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*. Nearly double the percentage of patients with moder

March 23, 2015 11:55

Positive Results from Phase III Study Evaluating Oral OTEZLA® (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

Celgene Corporation (NASDAQ:CELG) today announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4

March 23, 2015 11:40

Oral OTEZLA® (apremilast) Long-Term Safety and Efficacy Data in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD

Celgene Corporation (NASDAQ: CELG) today announced that results from long-term efficacy and safety analyses of the ESTEEM phase III clinical trial program of Otezla® (apremilast) were presented at the

March 23, 2015 11:20

Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference

Today Biogen Idec (NASDAQ:BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile

March 19, 2015 13:55

Queen Mary University of London Wins 2014 Terumo BCT Plasma Exchange Innovation Award

Terumo BCT is pleased to announce that Queen Mary University of London (QMUL) has been named the recipient of the 2014 Plasma Exchange Innovation Award (www.plasmaexchangegrant.com). The award is part

March 19, 2015 09:45

Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine

Celgene Corporation (NASDAQ:CELG) today announced that results from a double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 (mongersen) in patients with active Crohn'

March 17, 2015 10:20

Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces two analyses from the GLORIA™-AF Registry Program examining the use of anticoagulant treatments for stroke prevention in pa

March 17, 2015 08:50

Apgujeong YK Plastic Surgery Awarded Medical Tour Contribution Plaque for Its Excellence in Sanitary Inspection

Apgujeong YK Plastic Surgery was selected as an outstanding medical institution in sanitary inspection for operating rooms for its excellent hygienic conditions and honored with a Medical Tour Contrib

March 12, 2015 10:55

Nestlé Skin Health Announces Leadership Team

Nestlé Skin Health today announced organizational changes at top management level to support the company’s expanded market opportunity and ambition. “Our goal is to grow the number of people the compa

March 06, 2015 11:55

Modern Day Cold and Flu Experience Includes 35 Billion Sick Days and Coping on Social Media, According to Vicks® Global Survey

A new multi-country survey by Vicks®, the world’s #1 selling cough and cold brand*, revealed that the average person spends an astonishing three years of his/her life with a cold**. Globally consumers

March 04, 2015 10:15

Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada

For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency (EMA), U.S. F

March 03, 2015 17:00

ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-

February 26, 2015 13:55

Quintiles Receives Third Technology Security Award from IDG’s CSO Magazine

Quintiles (www.quintiles.com/news) announced today that it has been named to the 2015 CSO50 by IDG's CSO magazine (www.csoonline.com) in recognition of the company’s risk mitigation strategy managing

News by Region

News by Industry